levofloxacin has been researched along with hydroxychloroquine in 5 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (hydroxychloroquine) | Trials (hydroxychloroquine) | Recent Studies (post-2010) (hydroxychloroquine) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 5,885 | 474 | 4,041 |
| Protein | Taxonomy | levofloxacin (IC50) | hydroxychloroquine (IC50) |
|---|---|---|---|
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 2.951 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 4.772 | |
| Toll-like receptor 9 | Homo sapiens (human) | 0.11 | |
| Toll-like receptor 7 | Homo sapiens (human) | 3.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Azadi, H; Darabi, E; Fathi, S; Ghanei, M; Ghazale, AH; Ghazvini, A; Izadi, M; Jafari, R; Movaseghi, F; Mozafari, A; Panahi, Y; Parsaei, MR; Ranjkesh, MH; Rezapour, M; Saadat, SH; Salesi, M; Vahedi, E; Zand, N | 1 |
| Akbulut Koyuncu, İM; Kızıltunç, E; Uğurlu Ilgın, B | 1 |
| Abdulai, SI; Adewole, KE; Asogwa, NT; Ishola, AA; Tijjani, H | 1 |
1 review(s) available for levofloxacin and hydroxychloroquine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 other study(ies) available for levofloxacin and hydroxychloroquine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.
Topics: Adult; Aged; Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Hospitalization; Humans; Hydroxychloroquine; Iran; Length of Stay; Levofloxacin; Lopinavir; Male; Meropenem; Middle Aged; Naproxen; Oseltamivir; Pneumonia, Viral; Prednisolone; Retrospective Studies; Ritonavir; Treatment Outcome; Vancomycin | 2020 |
Effect of triple antimicrobial therapy on electrocardiography parameters in patients with mild-to-moderate coronavirus disease 2019.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Electrocardiography; Female; Humans; Hydroxychloroquine; Levofloxacin; Long QT Syndrome; Male; Middle Aged; Oseltamivir; Retrospective Studies; SARS-CoV-2; Severity of Illness Index; Treatment Outcome; Young Adult | 2021 |
Phylogenic analysis of coronavirus genome and molecular studies on potential anti-COVID-19 agents from selected FDA-approved drugs.
Topics: Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Coronavirus Nucleocapsid Proteins; COVID-19 Drug Treatment; Esterases; Hemagglutinins; Humans; Hydroxychloroquine; Levofloxacin; Ligands; Lopinavir; Molecular Docking Simulation; Molecular Dynamics Simulation; SARS-CoV-2 | 2022 |